Please login to the form below

Not currently logged in
Email:
Password:

ATTR cardiomyopathy

This page shows the latest ATTR cardiomyopathy news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

placebo in patients with ATTR cardiomyopathy, reducing the death rate from around 43% to 29.5%. ... Prior to Vyndaqel, treatment options for patients with ATTR cardiomyopathy were restricted to symptom management and – in rare cases – a heart

Latest news

  • Vyndaqel a bright spot as Pfizer comes under pressure Vyndaqel a bright spot as Pfizer comes under pressure

    following its FDA approval to treat ATTR cardiomyopathy last September. ... As of the end of 2019 more than 9, 000 ATTR cardiomyopathy patients had been diagnosed in the US – raising the diagnosis rate from 1% pre-Vyndaqel launch to around 9%,

  • Pfizer buys dwarfism drug company Therachon for $810m Pfizer buys dwarfism drug company Therachon for $810m

    The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM)

  • Speedy approval for Pfizer's Onpattro rival Speedy approval for Pfizer's Onpattro rival

    Approved in two different formulations. Pfizer’s blockbuster-in-waiting drug tafamidis has gained FDA approval to treat cardiomyopathy in patients with rare disease ATTR. ... Cardiomyopathy (CM) is the most serious of the symptoms seen in patients with

  • FDA lifts clinical hold on Sanofi’s haemophilia drug FDA lifts clinical hold on Sanofi’s haemophilia drug

    The company recently abandoned one of its gene-silencing drugs – revusiran for the rare disease hereditary ATTR amyloidosis with cardiomyopathy – although its new lead program patisiran for ATTR plus polyneuropathy remains

  • Alnylam pulls lead drug revusiran after deaths in phase III trial Alnylam pulls lead drug revusiran after deaths in phase III trial

    A phase III trial of revusiran in the rare disease hereditary ATTR amyloidosis with cardiomyopathy - which can cause nerve and heart damage - showed that more patients died on the drug than ... Patients with hereditary ATTR amyloidosis and cardiomyopathy

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...
Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...

Infographics